Genetic Variants in ASCT2 Gene are Associated with the Prognosis of Transarterial Chemoembolisation-Treated Early-Stage Hepatocelluar Carcinoma |
Ge, Nai-Jian
(Department of Radioactive Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University)
Shi, Zhi-Yong (Department of Radioactive Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University) Yu, Xiao-He (Department of Radioactive Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University) Huang, Xiao-Jun (State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University) Wu, You-Sheng (State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University) Chen, Yuan-Yuan (Department of Ophthalmology, First People of Yulin) Zhang, Jin (State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University) Yang, Ye-Fa (Department of Radioactive Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University) |
1 | Bruix J, Sherman M, American Association for the Study of Liver D (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. DOI |
2 | Chamary JV, Parmley JL, Hurst LD (2006). Hearing silence: non-neutral evolution at synonymous sites in mammals. Nat Rev Genet, 7, 98-108. DOI |
3 | Fuchs A, Colonna M (2006). The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin Cancer Biol, 16, 359-66. DOI |
4 | Fuchs BC, Finger RE, Onan MC, et al (2007). ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol, 293, 55-63. DOI |
5 | Hensley CT, Wasti AT, DeBerardinis RJ (2013). Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest, 123, 3678-84. DOI |
6 | Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. DOI |
7 | Kohles N, Nagel D, Jungst D, et al (2012). Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol, 33, 33-40. DOI |
8 | Li R, Younes M, Frolov A, et al (2003). Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res, 23, 3413-8. |
9 | Llovet JM, Bruix J (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatol, 37, 429-42. DOI |
10 | Llovet JM, Real MI, Montana X, et al (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 359, 1734-9. DOI |
11 | Mazurek S, Eigenbrodt E (2003). The tumor metabolome. Anticancer Res, 23, 1149-54. |
12 | Mullen AR, Hu Z, Shi X, et al (2014). Oxidation of alphaketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep, 7, 1679-90. DOI |
13 | Namikawa M, Kakizaki S, Kaira K, et al (2014). Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma. Hepatol Res. |
14 | Reynolds MR, Lane AN, Robertson B, et al (2014). Control of glutamine metabolism by the tumor suppressor Rb. Oncogene, 33, 556-66. DOI |
15 | Shastry BS (2009). SNPs: impact on gene function and phenotype. Methods Mol Biol, 578, 3-22. DOI |